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Abstract 
A systematic approach was developed to investigate the stability of gentamicin sulfate and 
gentamicin sulfate/poly (lactic-co-glycolic acid) coatings on hydroxyapatite surfaces. The influence of 
environmental factors (light, humidity, oxidation and heat) upon degradation of drug in the coatings 
was investigated using liquid chromatography with evaporative light scattering detection and mass 
spectrometry. Gentamicin sulfate coated rods were found to be stable across the range of 
environments assessed, with only an oxidizing atmosphere resulting in significant changes to the 
gentamicin composition. In contrast, rods coated with gentamicin sulfate/poly (lactic-co-glycolic 
acid) were more sensitive to storage conditions with compositional changes being detected after 
storage at 60 °C, 75% relative humidity or exposure to light. The effect of γ-irradiation on the coated 
rods was also investigated and found to have no significant effect. Finally, liquid chromatography-
mass spectrometry analysis revealed that known gentamines C1, C1a and C2 were the major 
degradants formed. Forced degradation of gentamicin coatings did not produce any unexpected 
degradants or impurities. 
Keywords 
Gentamicin, coatings, storage stability testing. 
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1. Introduction 
Over the past decade, scientists have been working at the frontier between materials science and 
pharmaceutics to develop new orthopedic devices with functionalized antibacterial coatings [1–5].  
This interest has been driven by the ongoing problem of periprosthetic joint infection in 0.3 to 9% of 
patients following total replacement of the hip, knee or ankle [6].  Patients with implanted devices 
are particularly susceptible to infection due to compromised host defense at the implant/tissue 
interface [1,7].  Furthermore, implant adherent bacteria typically exist as a biofilm, which protects 
the former from the host immune system and antibacterial agents [8,9].  Treatment of such bacterial 
biofilm usually requires surgical removal of the implant, followed by replacement in one or two 
stages depending on the nature of the infection [6].  Therefore, it becomes necessary to explore 
alternative procedures for preventing implant associated infections in the first instance. 
One such method is the application of antimicrobial coatings to the biomedical implant.  Such 
coatings can disrupt the adhesion of bacteria to the implant surface, and bolster the host’s immune 
system in the interface region between implant and tissue [1].  Gentamicin is the antibiotic most 
widely exploited in antibiotic coatings of implants due to its relatively broad antibacterial spectrum 
and thermal stability [1,3,4].  Other antimicrobials which have also been used in implant coatings 
include cephalothin [4], carbenicillin [4], amoxicillin [4], cefamandol [4], tobramycin [4], vancomycin 
[4,10,11], chlorhexidine [12], chloroxylenol [13], silver [14], copper [15], and zinc [16]. 
 
Fig. 1 Structure of gentamicin congeners as well as common impurities and degradants. 
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Gentamicin is an aminoglycoside antibiotic consisting of four major components (C1, C1a, C2, C2a) and 
a minor component C2b which are produced by fermentation of Micromonospora purpurea or 
Micromonospora echinospora (Fig. 1)  [17,18].  The ratio of the individual congeners is dependent on 
the origin of the sample and accepted limits to these ratios are specified in the US and EU 
Pharmacopoeias [19,20].  During the fermentation process a number of other minor impurities (e.g. 
sisomicin, and JI-20B) and degradation products (2-deoxystreptamine, and garamine) can also be 
formed (Fig. 1) [21].  Bulk gentamicin mixtures as an active pharmaceutical ingredient (API) are 
typically characterized by high performance liquid chromatography (HPLC) with the detection of the 
major components facilitated by UV detection of their ortho-phthaldehyde derivatives [22,23], 
pulsed electrochemical detection [24–26], charged aerosol detection [27] or evaporative light 
scattering detection (ELSD) [24,28,29]. Liquid chromatography–mass spectrometry (LC-MS) also has 
been employed to establish impurity profiles of gentamicin mixtures [30–32]. 
A particular formulation has been developed and investigated in previous studies [33–36], with the 
objective of clinical use in cementless hip prostheses.  In vitro testing of grit blasted and porous 
titanium coupons coated with 1.0 mg gentamicin per cm2 and a poly(lactic-co-glycolic acid) (PLGA) 
overcoat has shown them to be as efficacious as a commercially available antibiotic-loaded bone 
cement for preventing infection [33,34].  Subsequent in vivo studies have demonstrated both the 
antibacterial efficacy of this coating formulation and that it supports the integration of bone tissue 
into the implant surface through its relatively fast in vivo dissolution [35,36].  As part of this 
convergent technology development it is necessary to investigate the stability of the active drug 
coating under common sterilization and storage conditions used for medical implants. 
The degradation of gentamicin as a pure API or in solution, is well established [37]. However, 
alternative degradation pathways might be possible on interaction of gentamicin with the surface of 
a medical device. Friess and Schlapp [38] have reported the short term stability of gentamicin loaded 
PLGA microparticles and collagen/PLGA composites sterilized by ethylene oxide treatment as well as 
β- and γ-irradiation.  Ethylene oxide sterilization resulted in chemical changes to the gentamicin drug 
substance, while storage of irradiated samples at 40 °C and 75% relative humidity (RH) resulted in 
degradation of the polymer support.  To our knowledge there have been no reported studies for the 
degradative behavior of gentamicin on titanium or hydroxyapatite device surfaces. 
The goal of this study was to evaluate the degradation pathways of gentamicin coatings on 
hydroxyapatite implant devices under common storage conditions. While gentamicin is known to be 
a heat stable antibiotic when stored under standard conditions as an API, incorporation on the 
surface of a material may lead to different stability levels and degradation pathways. Accordingly, a 
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range of temperatures were studied to establish the thermal stability/lability of gentamicin on 
surfaces. The impact of sterilization by γ-irradiation of the drug/device combination products was 
also investigated.  To facilitate these studies a simple yet robust method was developed for the 
extraction of the drug coating from the combination devices.  Extracts of the drug coating were 
analyzed by HPLC with ELSD to determine the ratio of the major components in the gentamicin 
coating.  The extracts were also analyzed for common gentamicin degradants and impurities using 
LC-MS. In the present study gentamicin sulfate coated hydroxyapatite rods were used as a 
convenient model system for larger implant devices. 
2. Experimental 
2.1 Reagents and chemicals 
Gentamicin sulfate (GS) was obtained from Lek (Lubljana, Slovenia).  HPLC grade water, acetonitrile 
and methanol were from Sigma-Aldrich (St Louis, MO, USA).  Trifluoroacetic acid (99%) (TFA) was 
from Sigma-Aldrich.  Nitrogen gas (purity 99.995%) was supplied by BOC (Guildford, UK). GS and 
GS/PLGA coated hydroxyapatite rods were obtained from DePuy Synthes (Cork, Ireland), produced 
via a process equivalent to previous published work on this coating [35,36].  The rods were received 
in sealed aluminum foil pouch packaging. 
2.2 Instrumentation and chromatographic conditions 
2.2.1 LC-ELSD chromatographic conditions 
The LC-ELSD apparatus consisted of an 1120 Compact LC system, a 385-ELSD evaporative light 
scattering detector and ChemStation B.04.03 software (all from Agilent Technologies, Santa Clara, 
CA, USA) for data acquisition.  Nitrogen (purity 99.995%) was used as the evaporation gas at a flow 
rate of 1.6 L/min.  ELSD was operated with the nebulizer and evaporator temperatures of 40°C. 
The LC-ELSD method was adapted from those previously reported by Agilent Technologies[39] and 
Clarot et al. [28].  An Atlantis T3 C18 column (150 mm x 4.6 mm, 5 µm, Waters, Milford, MA, USA) 
maintained at 25 °C in the 1120 Compact LC column heater, was used for chromatography.  The 
mobile phase was an isocratic mixture of an aqueous solution of trifluoroacetic acid (0.2 mol/L, pH 
1.5) and methanol in a ratio of 92:8 (v/v).  The mobile phase flow rate was 1 mL/min. 
All GS standard solutions were prepared in water.  The injection volume was 10 µL.  GS standards 
were prepared at concentrations of 0.1 to 1 mg/mL and used to calibrate the detector response. 
2.2.2 LC-MS chromatographic conditions 
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The LC-MS apparatus consisted of a 2695 Separations Module, a 2996 Photodiode Array Detector, a 
LCT Premier KD160 mass spectrometer and MassLynx 4.1 software (all from Waters, Milford, MA, 
USA) for data acquisition. Chromatographic column and conditions employed for LC-MS studies were 
the same as given above for the LC-ELSD data generation. 
2.2.3 1H Nuclear Magnetic Resonance (NMR) spectroscopy analysis 
1H NMR spectra were recorded in D2O on a Bruker Avance NMR spectrometer operating at 600 MHz 
at room temperature (20 °C). 
2.3 Isolation of gentamicin sulfate components  
Pure samples of the major components of GS were isolated using the LC-ELSD.  An initial analysis of 
GS performed using the LC-ELSD method reported above with an injection volume of 50 µL, provided 
retention times for the C1a, C2, C2a, and C1 components.  The ELSD detector was subsequently 
disconnected and fractions of the eluent collected from the detector inlet at the previously 
determined times (C1a 5.0 - 6.0 min, C2 6.9 – 7.9 min, C2a 9.0 – 9.9 min, C1 11.0 – 12.0 min).  Fifteen 
injections of a 0.25 mg/mL GS solution were processed.  Evaporation to dryness of the pooled 
fractions provided samples of gentamicin C1a, C2, C2a, and C1 in good purity, as determined by LC-
ELSD, NMR spectroscopy and HRMS. 
2.4 Chemical stability 
The stability of GS coated rods under a range of storage conditions was studied over 30 days.  The 
variation of storage conditions investigated are detailed below: 
 Thermal: Samples were stored at low temperatures (4 °C) or high temperature (60 °C) in 
sealed vessels to establish the thermal stability of the gentamicin on the rods. 
 Sensitivity to oxidation: Oxidising storage conditions were simulated by suspension of 
samples over a solution of 30% (m/m) hydrogen peroxide, while in contrast to simulate 
storage in a non-oxidising environment samples were stored under nitrogen gas at 20 °C. 
Both were shielded from light. 
 Humidity: Humidity variations were simulated by sample storage at low humidity (20% RH, 
suspension over saturated potassium acetate solution) or high humidity (75% RH, 
suspension over saturated sodium chloride solution) in sealed containers at 20 °C [40]. 
 Light:  Low light storage conditions were simulated by storage of the samples in open foil 
pouches at 20 °C while high light conditions were achieved by storage of the samples under 
a fluorescent light. 
6 
 
 
 Irradiation: GS coated rods were subjected to sterilisation by -ray irradiation (carried out by 
DePuy Synthes) at low (25 kGy) and high (40 kGy) doses [41].   
On completion of the storage period, the organic material was extracted from the coated 
hydroxyapatite rods by immersion in a solution of TFA/acetonitrile/water (0.3/3/97) [200 mL]. The 
vessels were sonicated for 1 h at room temperature. The resulting solution was filtered and 
evaporated to dryness.  Portions of the residues (10 mg) were dissolved in water (1 mL) and 
analyzed by LC-ELSD and LC-MS.  LC-ELSD results were recorded as % (m/m) based on the 
assumption that structurally similar gentamicin congeners have the same ELSD response factors [42].  
LC-MS results were recorded as peak area ratios relative to the gentamicin C1 peak area. 
Table 1 Environments for chemical stability tests. 
Environment Conditions 
Low Light Rods were stored in the foil pouch packaging with a small opening to allow for air penetration at 20 oC in the 
dark. 
High Light Rods were removed from the foil pouch and placed under a fluorescent lamp. 
Low Temperature Rods were stored in the sealed foil pouch packaging and refrigerated at 4 °C. 
High Temperature Rods were stored in the sealed foil pouch packaging in an oven at 60 °C. 
Low Humidity Rods were stored in the foil pouch packaging, with a small opening to allow for air penetration, and 
suspended in a sealed container containing a saturated potassium acetate solution at 20 oC (20% RH). 
High Humidity Rods were stored in the foil pouch packaging, with a small opening to allow for air penetration, and 
suspended in a sealed container containing a saturated sodium chloride solution at 20 oC (75% RH). 
Low Oxidation Rods were stored in opened foil pouches, shielded from light, at 20 oC, under a nitrogen atmosphere. 
High Oxidation Rods were stored in opened foil pouches, shielded from light, at 20 oC, suspended over a solution of 30% 
hydrogen peroxide. 
Low Irradiation Rods in their sealed foil packaging were subjected to a standard gamma dose (25 kGy) 
High Irradiation Rods in their sealed foil packaging were subjected to a high gamma dose (40kGy). 
As summarized in Table 1, the samples of GS coated rods were originally received in sealed foil 
pouches under a protective atmosphere.  For the light, humidity and oxidation stability tests the 
pouches were opened to enable exposure of the coating to the appropriate test conditions.  
Accordingly exposure to open atmosphere in addition to the specific stability tests is incorporated in 
the study. 
3. Results and discussion 
3.1 Analysis of bulk gentamicin sulfate 
The European Pharmacopoeia (EU Pharm.) defines acceptable limits for the composition of 
gentamicin sulfate (Table 2) [19].  The bulk gentamicin sulfate used for preparing coated devices in 
this study was examined using LC-ELSD to determine its composition before the application of the 
device coating (Fig. 2).  The composition of the bulk material was also determined separately using 
1H NMR spectroscopy.  The anomeric protons of the four gentamicin constituents could be 
separately assigned by resolution of the signal at 5.9 ppm.  Integration of this signal revealed the 
ratio of gentamicin components shown in Table 2 [43].  The LC-ELSD and 1H NMR spectroscopy 
determinations for our bulk gentamicin were in agreement, and were within the EU Pharm. limits.  
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This also verified that the major components of gentamicin sulfate displayed an equivalent response 
in ELSD detection. 
 
Fig. 2 LC-ELSD chromatogram of gentamicin sulfate [39]. 
 
Table 2 Composition (m/m) of bulk GS determined by LC-ELSD and 
1
H NMR spectroscopy. 
Methods Components (%, m/m)   
 C1 C1a C2 (C2+C2a+C2b) 
EU Pharm.  25-45 10-30 35-55 
LC-ELSD 38 11 51 
1H NMR 37 14 49 
 
3.2 Isolation of gentamicin sulfate components  
The individual gentamicin C1, C1a, C2 and C2a congeners were isolated using HPLC to provide pure 
standards for use in our LC-ELSD and LC-MS analysis.   
3.3 Chemical analysis of gentamicin coated hydroxyapatite devices 
In order to study the gentamicin coating on medical devices it was desirable to have a method for 
the extraction of the coating into a solution.  The extraction of the gentamicin coating could be 
effectively achieved by sonication of the coated rods in a solution of trifluoroacetic acid, acetonitrile 
and water in a ratio of 0.3:3:97 (v/v/v) at room temperature.  Subsequent analysis of the 
concentrated extract by LC-ELSD revealed a gentamicin composition of 41% C1, 8% C1a, 43% C2 and 
8% C2a.  While this composition was marginally outside of the EU pharmacopoeia specification for 
gentamicin drug product, it was considered sufficiently close to that of the bulk GS to indicate that 
the extraction method was efficient and non-destructive. 
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3.4 Stability of the gentamicin sulfate coating studied by LC-ELSD 
One of the core objectives of this study was to assess the chemical stability of gentamicin coatings 
on hydroxyapatite devices and determine if there were environmental factors impacting on shelf 
life.  For the purpose of this pilot study, GS coated hydroxyapatite rods supplied by DePuy Synthes 
were subjected to a 30 day forced degradation study to determine the influence of temperature, 
humidity, atmospheric oxidation and light exposure.  For these stability studies, it was important 
that the sealed foil pouches in which the rods were supplied were opened for the stability tests 
(other than thermal and irradiation studies) to evaluate effect of exposure to stress factor as 
compared to the packaged products. Also the hydroxyapatite rods coated with both GS and PLGA 
were subjected to the same forced degradation studies. 
 
Fig. 3 The effect of 30 day storage conditions on the composition of the GS coating determined by HPLC-ELSD.  
Control: control extraction, GR: GS coated rod, GPR: GS and PLGA coated rod, LT: stored at °4 C, HT:  stored at 60 °C, LH: 
stored under 20% RH, HH: stored under 75% RH, LL: stored in dark, HL: stored under light, LO: stored under nitrogen 
atmosphere, HO: stored over 30% H2O2. 
3.4.1 Temperature stability 
Gentamicin is well noted for being a heat stable antibiotic, retaining its activity even after 
autoclaving [44,45].  It is this stability under autoclave conditions that makes it a favored antibiotic 
for use in antimicrobial coated devices [1,3,4].  In the present study, storage of the rods in sealed 
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pouches at temperatures of 4 °C and 60 °C had no noticeable effect on the chemical composition of 
the coating consisting of just GS (Fig. 3A).  When the rods coated with both GS and PLGA were stored 
at 60 °C in sealed pouches, the resulting gentamicin composition showed a small but significant 
reduction in the level of C2 (43% down to 36%) relative to the other congeners.  This result indicates 
that the thermal stability of GS may be reduced in coatings containing PLGA. 
3.4.2 Stability to humidity 
The International Pharmacopoeia describes gentamicin sulfate as being hygroscopic and susceptible 
to gradual degradation on exposure to a humid atmosphere with the decomposition being faster at 
higher temperatures [46].  Storage of the GS and GS/PLGA coated rods in the opened foil packaging 
at a low relative humidity (RH) of 20% resulted in no change to the congener ratios of gentamicin in 
the coating.  However, storage of both types of coated rods at 75% RH resulted in small decreases in 
the level of gentamicin C2 relative to the other congeners (Fig. 3B).  The presence of PLGA in the 
coating had little effect on the stability of gentamicin under high humidity.  The changes observed in 
this study were relatively small but it should be noted that the high RH test was conducted at room 
temperature over a limited period of 30 days.  A combination of high RH and high temperature 
might be expected to exert more of an effect on the gentamicin coating over longer time periods.  
3.4.3 Stability to atmospheric oxidation 
Oxidative processes are known to occur in the biosynthetic interconversion of gentamicin and its 
several known impurities such as JI-20B [47].  It was therefore expected that an oxidizing 
atmosphere might lead to degradation of gentamicin.  Also the amino and hydroxyl functional 
groups in GS are reported as being susceptible to chemical oxidation [37].  Furthermore, the 
glycoside linkages of several aminoglycosides are known to be cleaved under oxidizing conditions 
[48].  In the present study no changes were observed in the composition of GS and GS/PLGA coatings 
stored in open pouches under an inert nitrogen atmosphere.  Storage of the coated rods in open 
pouches in an oxidizing atmosphere, over a solution of hydrogen peroxide (30%, m/m) resulted in 
measurable changes to the gentamicin composition of GS and GS/PLGA coatings.  Small increases in 
the relative level of gentamicin C2 were observed, while gentamicin C1 was noticeably decreased 
from 41% to 34% in both the GS and GS/PLGA coating.  
3.4.4 Stability to light exposure 
Hydroxyapatite rods coated with either GS or GS/PLGA were stored in the dark and under a 
fluorescent light for 30 days in an open atmosphere in both cases.  After this period of storage, no 
changes where observed in the gentamicin composition of rods stored in the dark (Fig. 3D).  The GS 
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coated rod also appeared to be stable to storage under the fluorescent lamp with no measurable 
change in the gentamicin congener ratios measured by LC-ELSD, while  the GS/PLGA coated rod did 
undergo changes in the same when stored under the lamp.  Under the high light exposure 
conditions, the C2 level was significantly reduced to 31% in the GS/PLGA coating.  This indicated that, 
even though gentamicin appeared to be stable to light, the presence of other components (such as 
PLGA) in antimicrobial coatings could lead to significant photodegradation.  
3.5 Analysis of common impurities by LC-MS 
The extracts obtained from the stability studies were also subjected to LC-MS analysis to screen for 
common gentamicin impurities and degradants. The characteristic ions for many of these gentamicin 
impurities have been previously reported [30–32].  Total ion count chromatograms showed the 
presence of the five gentamicin C components. The presence of key degradants and impurities in the 
extracts were determined by ion extraction method. 
Garamine fragmentation ions were detected in all samples as multiple peaks due to fragmentation 
of the major gentamicin congeners inside the mass spectrometer. However, m/z 322 peak was also 
observed at 2.59 min which was not observed with any heavier ions, suggesting that this peak 
represented garamine degradants which formed prior to LC-MS analysis.  Measurement of this peak 
in the extracts revealed garamine levels of 1%-6% with the maximum level being observed in 
samples stored under a highly oxidizing atmosphere (5%-6%). No garamine was detected in the 
control extract taken from a rod not subjected to forced degradation studies. 
The extracts were expected to contain gentamines in significant levels if severe degradation of the 
corresponding gentamicin C components had occurred under the tested environmental conditions. 
Gentamine C1, arising from degradation of gentamicin C1, was observed at levels of 2-5% in most 
extracts. However, there was noticeably more gentamine C1 (19%) observed in samples subjected to 
highly oxidizing conditions. Conditions of low humidity also led to an increase in gentamine C1 levels 
(7%-9%). The C1a and C2 gentamines showed a similar increase in levels for samples that experienced 
a highly oxidizing atmosphere.  
G-418, sisomicin and JI-20B are common in batches of GS and are related to gentamicin through 
biotransformative processes [47].  Sisomicin and the antibiotics JI-20B and G-418 were observed at 
levels below 1% in all the samples. 
The storage conditions employed in this study generally had little effect on the composition and 
degradation of the gentamicin coated rods; the exception being the highly oxidizing environment. 
After 30 days the only major degradants observed were gentamines arising from the cleavage of the 
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A-ring from the B-C gentamicin ring system. All the LC-MS peaks observed in this study could be 
attributed to previously reported gentamicin impurities [30–32]. Thus, there was no evidence that 
gentamicin undergoes substantive unique degradation pathways when applied as a device coating at 
readily detectable levels 
 
Fig. 4 The effect of 30 day storage conditions on relative level of common impurities in the GS coating determined by  
LC-MS.  Control: control extraction, GR: GS coated rod, GPR: GS and PLGA coated rod, LT: stored at °4 C, HT:  stored at 60 
°C, LH: stored under 20% RH, HH: stored under 75% RH, LL: stored in dark, HL: stored under light, LO: stored under nitrogen 
atmosphere, HO: stored over 30% H2O2. 
3.6 Stability to γ-irradiation 
γ-Irradiation is a common method for the sterilization of medical devices and has previously been 
employed for gentamicin containing PLGA composite particles [38].  Friess and Schlapp have 
reported that free radicals, detected by electron spin resonance spectroscopy, were formed in 
gentamicin loaded particles sterilized by exposure to 28.9 kGy or γ-irradiation.  These free radicals 
did not persist beyond four weeks in gentamicin and had no detectable effect on the 1H NMR 
spectrum of gentamicin.[38]  In our study, we employed 25 kGy and 40 kGy dosages of γ-irradiation 
to sterilize GS and GS/PLGA coated hydroxyapatite rods.  LC-ELSD and LC-MS analysis of extracts 
after low and high dose γ-irradiation did not display any significant changes compared to extracts 
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from unsterilized rods (Fig. 5). These results confirm that γ-irradiation is a suitable sterilization 
method for use with gentamicin coated medical implants. 
Fig.5 (a) The effect of -irradiation on the GS composition (measured by HPLC-ELSD) and (b) the relative levels of common 
GS impurities (measured by LC-MS).  Control: control extraction, GR: GS coated rod, GRP: GS and PLGA coated rod. 
 
 
As stated, LC-ELSD analysis revealed that the change in composition of the gentamicin congeners 
(gentamicin C1, C1a, C2 and C2a) was very small across the range of conditions studied. The largest 
variation was seen is for rods stored under high humidity and oxidation. The proportion of 
gentamicin C2 changed by 5% [Fig. 3(B) and 3(C)]. A comparison of the change in composition of the 
minor impurities using LC-MS (Fig. 6) reveals that the biggest change was seen in the amounts of 
gentamine C1 formed after storage. Under conditions of low humidity both GS coated rods and those 
coated with GS and PLGA showed a significant increase in levels of gentamine C1 detected. This 
effect is even more pronounced when rods subjected to highly oxidizing conditions were examined. 
In addition, an increase in the other gentamine impurities (gentamines C1a and C2) was also evident. 
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Fig. 6 Comparison of change in composition of impurities in the GS and GS and PLGA coated rods by LC-MS.  Control: 
control extraction, LT: stored at °4 C, HT:  stored at 60 °C, LH: stored under 20% RH, HH: stored under 75% RH, LL: stored in 
dark, HL: stored under light, LO: stored under nitrogen atmosphere, HO: stored over 30% H2O2, siso: sisomicin, g-c1: 
gentamine C1, g-1a: gentamine C1a, g-c2: gentamine C2. 
 
4. Conclusions 
GS and GS/PLGA coated hydroxyapatite rods were subjected to high and low temperature, humidity, 
oxidation and light exposure environments over a period of 30 days.  LC-ELSD and LC-MS analysis of 
extracts from GS coated rods indicated that they were stable to storage at 60 °C and also to light 
exposure.  High humidity had a minimal effect on the composition of GS.  In contrast, rods coated 
with both GS and PLGA were more sensitive to storage conditions with compositional changes being 
detected after storage at 60 °C, 75% RH or exposure to light.  Storage of both GS and GS/PLGA 
coated rods in an oxidizing atmosphere resulted in significant changes to the gentamicin 
composition but no unexpected impurities were detected by LC-MS.  The major degradants detected 
were the gentamines arising from degradation of the corresponding gentamicin C-components.  
Finally, the effect of γ-irradiation on the gentamicin composition of GS and GS/PLGA coated rods was 
also investigated and found to have no significant effect. Based on this preliminary study, 
investigation of long term storage of the GS and GS/PLGA coated rods under appropriately 
14 
 
 
controlled conditions (namely protected from light, avoiding high temperature and exposure to air) 
is warranted. 
In conclusion a systematic approach has been developed to investigate the chemical stability of drug 
coatings applied to medical implant devices.  This methodology was applied to the study of 
hydroxyapatite rods coated with gentamicin to determine the degradative behavior of gentamicin 
on a device surface.  
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Highlights 
 Method developed for extraction and analysis of an antimicrobial coated orthopedic device. 
 Evaluated the effect of light, humidity, oxygen and heat on the storage stability of drug 
coatings. 
 Also evaluated the influence of -ray sterilization on the chemical composition of drug 
coatings. 
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